This is the authors' abstract. We don't add key points for this paper.
•Overall prognosis of uterine leiomyosarcoma (ULMS) is poor with a low 5-year survival rate.•Microsatellite instability (MSI)-high ULMS is not well documented in current literature.•Immune checkpoint inhibitors such as pembrolizumab have been shown to have good efficacy in treating MSI-high solid tumors.•Targeting MSI-high ULMS with pembrolizumab can potentially maintain a patient's quality of life and extend overall survival.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: